Welcome to the first edition of Changing Faces for 2025. January kicked off the year with a flurry of notable leadership transitions across the pharmaceutical and biotechnology sectors.

欢迎来到2025年首期《变革面孔》。一月拉开了新年的序幕，制药和生物技术领域出现了许多显著的领导层更替。

Here is a detailed look at the latest hires and departures.

以下是最新招聘和离职的详细情况。

End of an era at Takeda.

武田时代的终结。

After leading Japan's largest drugmaker for 11 years,

在领导日本最大的制药商11年后，

Christophe Weber

克里斯托夫·韦伯

announced his

宣布了他的

planned departure from Takeda

计划离开武田

in June 2026. Weber, who has steered the pharmaceutical giant through significant transformations, will be succeeded by Julie Kim, who joined Takeda in 2019, marking a carefully orchestrated leadership transition for the company.

2026年6月，韦伯将卸任。他带领这家制药巨头经历了重大的转型。接替他的是2019年加入武田的朱莉·金，这标志着该公司一次精心策划的领导层交接。

Notable departures continue.

值得注意的离职仍在继续。

The industry saw other significant exits, with

该行业还出现了其他重大退出，

Richard J Law

理查德·J·劳

departing Exscientia (now Recursion) after four years as chief business officer, while

在担任首席商务官四年后，离开Exscientia（现为Recursion），同时

Adam Townsend

亚当·汤森

stepped down from his COO position at Apellis to pursue a CEO role at a private biotechnology company. Townsend, who joined Apellis in 2018, played a crucial role in the organisation's transition to a commercial-stage company and built a strong foundation for future growth.

辞去了他在Apellis的首席运营官职位，转而担任一家私人生物技术公司的首席执行官。汤森于2018年加入Apellis，在推动该组织向商业阶段公司转型中发挥了关键作用，并为未来的增长奠定了坚实的基础。

CEO appointments bring fresh leadership.

首席执行官的任命带来了新的领导力。

January witnessed a wave of chief executive appointments across the biotechnology and pharmaceutical landscape:

一月，生物技术和制药领域出现了一波首席执行官任命潮：

Dr Joerg Moeller

约尔格·穆勒博士

took the helm at Antag Therapeutics, a biopharmaceutical company developing novel therapies for obesity and cardiometabolic diseases. Moeller brought extensive experience from Bayer AG's Pharmaceutical Division, where he led global R&D and spearheaded strategic AI collaborations.

接手了Antag Therapeutics的领导权，这是一家致力于开发肥胖症和心脏代谢疾病新疗法的生物制药公司。莫勒尔从拜耳医药部门带来了丰富的经验，在那里他领导了全球研发并推动了战略性的人工智能合作。

Dr William S Marshall

威廉·S·马歇尔博士

joined Ribometrix as CEO, following his tenure as president, CEO, co-founder, and director of miRagen, an RNA-based therapeutics company. Previously, he served as vice president of technology and business development for bioscience at Thermo Fisher Scientific.

在担任基于RNA的治疗公司miRagen的总裁、首席执行官、联合创始人和董事之后，加入Ribometrix担任首席执行官。此前，他曾担任赛默飞世尔科技生物科学部门的技术和业务发展副总裁。

After overseeing an $85 million Series A financing at Ambagon Therapeutics,

在 Ambagon Therapeutics 监督了 8500 万美元的 A 轮融资后，

Scott Clarke

斯科特·克拉克

stepped in as CEO at CatalYm, a drug development company advancing visugromab, a first-in-class anti-GDF-15 antibody for solid tumours.

接任CatalYm公司首席执行官一职，该公司是一家致力于开发visugromab（一种用于实体瘤的首创抗GDF-15抗体）的药物研发公司。

Scientific leadership sees major shifts.

科学领导力出现重大转变。

Several companies strengthened their scientific teams with key CSO appointments:

几家公司在关键的首席科学官任命上加强了他们的科学团队：

Dr Jacques Dumas

雅克·杜马斯博士

joined AiCuris from Arrakis Therapeutics, where he had led R&D activities and managed high-profile collaborations with Roche and Amgen. AiCuris focuses on developing precise therapies for immunocompromised patients requiring effective infection treatments.

加入AiCuris之前，他在Arrakis Therapeutics领导研发活动，并管理与罗氏和安进的高知名度合作。AiCuris专注于为需要有效感染治疗的免疫功能低下患者开发精准疗法。

Dr Margit Janat-Amsbury

玛吉特·雅纳特-安斯伯里博士

moved to Halia Therapeutics as CSO after serving as CMO at the same company. Halia is pioneering novel therapeutics for patients with chronic inflammatory disorders and neurodegenerative diseases.

在同一家公司担任首席医学官后，转任哈利亚治疗公司（Halia Therapeutics）的首席科学官。哈利亚正在为患有慢性炎症性疾病和神经退行性疾病的患者开创全新疗法。

Matthew Fyfe

马修·费夫

took the CSO position at Outrun Therapeutics following his role as senior vice president of therapeutics at Storm Therapeutics. Fyfe brings experience delivering clinical candidates that have reached Phase 2 and beyond in several disease areas.

在Storm Therapeutics担任治疗高级副总裁后，Fyfe接任了Outrun Therapeutics的首席科学官职位。Fyfe在多个疾病领域中，拥有将临床候选药物推进至二期及更高阶段的经验。

Prof Dr Uli Brödl

乌尔里希·布罗德尔教授博士

joined Grünenthal from Boehringer Ingelheim, where he served as corporate senior vice president and head of global clinical development & operations.

加入Grünenthal之前，他在Boehringer Ingelheim担任公司高级副总裁以及全球临床开发与运营主管。

RNA specialist

RNA专家

Dr Katie Warner

凯蒂·华纳博士

became CSO at Ribometrix, the company she co-founded. Warner was an early pioneer of RNA SHAPE technologies and demonstrated the first structure-based proof-of-principle that RNA is targetable by fragments.

成为她共同创立的公司Ribometrix的首席科学官。Warner是RNA SHAPE技术的早期先驱，并首次通过基于结构的原理证明RNA可被片段靶向。

Medical leadership appointments.

医学领导职位的任命。

Dr Federico Grossi

费德里科·格罗西博士

took on the CMO role at UNITY Biotechnology, bringing extensive experience from Apellis Pharmaceuticals. At Apellis, Grossi oversaw clinical strategy and development programmes in ophthalmology, haematology, neurology, and nephrology, leading to the approval and commercial launch of EMPAVELI and SYFOVRE..

接任UNITY Biotechnology的首席医学官（CMO）职位，带来了来自Apellis Pharmaceuticals的丰富经验。在Apellis期间，Grossi负责眼科、血液科、神经科和肾科的临床策略与开发项目，领导了EMPAVELI和SYFOVRE的获批及商业化上市。

Business and commercial leadership expands.

商业和企业领导力在扩展。

Multiple companies bolstered their business and commercial teams with strategic hires:

多家公司通过战略性招聘加强了他们的业务和商业团队：

Former chief business officer of Agios Pharmaceuticals,

前Agios Pharmaceuticals首席商务官，

Charlotte Newman

夏洛特·纽曼

, joined Cardurion Pharmaceuticals as CBO. Newman previously held strategic product and portfolio roles at Biogen.

，加入Cardurion Pharmaceuticals担任首席商务官。纽曼之前在百健（Biogen）担任过战略产品和投资组合相关职务。

After serving as VP global business development at Evotec,

在Evotec担任全球业务发展副总裁之后，

Hannah Seitz

汉娜·塞茨

became CBO at LabGenius, a drug discovery company pioneering machine learning for therapeutic antibody discovery.

成为LabGenius的首席商务官，这是一家开创机器学习用于治疗性抗体发现的药物发现公司。

Jamie Coleman

杰米·科尔曼

took the chief commercial officer position at Kailera Therapeutics after holding key roles at Eli Lilly, most recently serving as vice president, US brand leader for Zepbound.

在加入凯勒拉治疗公司担任首席商务官之前，曾在礼来公司担任过多个关键职位，最近一次是担任Zepbound的美国品牌负责人副总裁。

Dan Monahan

丹·莫纳汉

joined Amylyx Pharmaceuticals as CCO from Otsuka Pharmaceuticals, where he led the US commercialisation efforts for the company's CNS franchise, including REXULTI and ABILIFY MAINTENA.

加入Amylyx制药公司担任首席商务官，之前在大冢制药工作，他在那里领导了公司中枢神经系统特许经营在美国的商业化工作，包括REXULTI和ABILIFY MAINTENA。

Following a successful tenure at Astrea Bioseparations,

在Astrea Bioseparations任职成功后，

Gabe Longoria

加布·隆戈里亚

moved to 4basebio as CCO. 4basebio develops and commercialises large-scale manufacture of synthetic DNA and nanoparticle delivery solutions.

转至4basebio担任首席商务官。4basebio致力于开发和商业化大规模合成DNA和纳米颗粒递送解决方案的生产。

Vice president and senior leadership roles filled.

副总裁和高层领导职位已填补。

Several companies strengthened their leadership teams with strategic vice president appointments:

几家公司在战略上任命了副总裁，从而加强了他们的领导团队：

Giancarlo Benelli

詹卡洛·贝内利

became senior VP and head of Europe at BeiGene after serving as general manager at Advanced Accelerators Applications, where he successfully launched Lutathera in both France and Italy.

在加入百济神州担任欧洲高级副总裁兼负责人之前，他曾任Advanced Accelerators Applications总经理，并成功在法国和意大利推出了Lutathera。

Halia Therapeutics made two key appointments with

Halia Therapeutics 做出了两项关键任命，

Tracey Clayton

特雷西·克莱顿

joining as VP of program mnagement & clinical operations from Sumitomo Pharma America, and

加入后担任项目管理与临床运营副总裁，此前就职于住友制药美国公司，且

Stephen Anthony

史蒂芬·安东尼

taking the senior VP of clinical development role.

担任临床开发高级副总裁的职务。

Sciensus welcomed

欢迎Sciensus

Alastair MacDonald

阿拉斯泰尔·麦克唐纳

as VP of medical affairs after 20 years at AstraZeneca and Syneos Health, while

在阿斯利康和Syneos Health工作20年后，担任医疗事务副总裁，同时

Dr Raymond A. Huml

雷蒙德·A·胡尔博士

joined as VP of rare & orphan disease strategy, with over 25 years of industry experience.

加入公司担任罕见病与孤儿药战略副总裁，拥有超过25年的行业经验。

James Christensen

詹姆斯·克里斯滕森

moved to Terremoto Biosciences as president and head of R&D after serving as chief scientific officer at Mirati, where he oversaw drug discovery, early clinical development, manufacturing, and companion diagnostics.

在担任Mirati的首席科学官之后，他转任Terremoto Biosciences的总裁兼研发主管，在Mirati期间，他负责监督药物发现、早期临床开发、制造和伴随诊断。

With 25 years of experience in healthcare,

拥有25年的医疗保健经验，

Faruk Uzman

法鲁克·乌兹曼

took on an expanded role at Boston Scientific as vice president for healthcare solutions & partnerships and remote sales for Europe, Middle East, and Africa.

在波士顿科学公司担任副总裁，负责欧洲、中东和非洲的医疗解决方案与合作伙伴关系以及远程销售的扩展角色。

Financial leadership strengthened.

财务领导能力增强。

Juan Graham

胡安·格雷厄姆

joined Perspective Therapeutics as CFO after serving at FibroGen, a global emerging growth biopharmaceutical company. Meanwhile,

在加入Perspective Therapeutics担任首席财务官之前，他曾在全球新兴成长型生物制药公司FibroGen任职。与此同时，

David Schilansky

大卫·希兰斯基

, who previously co-headed DBV Technologies and led two IPOs on Euronext and Nasdaq with more than one billion US dollars raised, became CFO at Ariceum Therapeutics.

此前曾共同领导DBV Technologies并带领公司在泛欧交易所和纳斯达克进行了两次IPO，筹集了超过10亿美元的资金后，成为了Ariceum Therapeutics的首席财务官。

Technology and operations see new faces.

技术和运营部门迎来了新面孔。

Wafaa Mamilli

瓦法·马米利

joined Roche as chief digital technology officer after holding the role of chief digital & technology officer at Zoetis. And

在担任佐伊蒂斯首席数字和技术官后，加入罗氏担任首席数字技术官。并且

Dr Michael Ringel

迈克尔·林格尔博士

took the COO position at Life Biosciences, moving from Boston Consulting Group where he served as managing director and senior partner advising biotech and pharmaceutical clients.

接任了Life Biosciences的首席运营官职位，他之前在波士顿咨询集团担任董事总经理和高级合伙人，为生物技术和制药客户提供咨询服务。

Additional appointments round out the month.

额外的预约使这个月的安排更加圆满。

Rachel Kalmar

蕾切尔·卡尔马尔

joined Moderna as principal product manager from Biogen, and

加入Moderna担任首席产品经理，之前在Biogen工作，

Kristin Politi

克里斯汀·波利蒂

moved to BMS as associate director of strategy & media relations after serving as VP of media relations at LifeSci Communications.

在LifeSci Communications担任媒体关系副总裁后，转至BMS担任战略与媒体关系副主管。

That's it for this month's edition of Changing Faces. Remember, if you've had a recent appointment and you work in or around the pharma space, we want to hear about it. Please send your press releases to editorial@pharmaphorum.com to be included in future editions of Changing Faces.

以上就是本月《Changing Faces》的全部内容。记住，如果你最近有任命，并且你在医药领域工作或周边行业，我们希望听到你的消息。请将你的新闻稿发送至 editorial@pharmaphorum.com，以便在未来的《Changing Faces》版本中被收录。